TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01520298

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For the control group, a total of 100 mLs of 0.9% sodium chloride will be transferred to a Hospira LifeCare container and infused over 15 minutes (6.7 mL/min). A beyond use expiration of 6 hours will be placed on the container. All admixture manipulations will be completed by the pharmaceutical staff according to the chapter 797 guidelines in the U.S. Pharmacopoeia. The treatment period will begin after admission and randomization, and will continue until surgical intervention.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen IV
Description: For the treatment group, a total of 100 milliliters (mLs) of acetaminophen (1000 mg) will be transferred to a Hospira LifeCare container and infused over 15 minutes (6.7 mLs/min). A beyond use expiration of 6 hours at room temperature will place on the container, as recommended by the manufacturer. All admixture manipulations will be completed by the pharmaceutical staff according to the chapter 797 guidelines in the U.S. Pharmacopoeia. The treatment period will begin after admission and randomization, and will continue until surgical intervention.
Study: NCT02997371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra Prefilled Syringe
Description: Administration as initially intravenous injection followed by a intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra Prefilled Syringe
Description: Administration as initially intravenous injection followed by a intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline
Description: Placebo, administration as initially intravenous injection followed by a intravenous infusion
Study: NCT04777526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioception exercises
Description: Exercises for recognition of thumb position and thumb force sense.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Joint protection program
Description: Reeducation in the activities daily life

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Joint protection program
Description: Reeducation in the activities daily life

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thumb orthosis
Description: Thumb night orthosis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thumb orthosis
Description: Thumb night orthosis

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual distraction
Description: Manual distraction of CMC joint

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual distraction
Description: Manual distraction of CMC joint
Study: NCT01012479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil and hydrochlorothiazide
Description: Candesartan cilexetil 16 mg, tablets, orally, once daily for 1 week; increased to candesartan cilexetil 16 mg and hydrochlorothiazide 12.5 mg combination tablet, orally once daily for 2 weeks; then increased to candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg combination tablets, orally, once daily for up to 6 weeks
Study: NCT02918760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: This group will include (32) women according to inclusion and exclusion criteria and will receive a card of Gabapentin which will be taken orally by the patient at home three times daily and maximum dose 2700mg per day by 300 mg increments each week until sufficient pain relief, or the occurrence of side effects such as dizziness, somnolence, edema and ataxia.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Group B (controls):This group will include (32) women according to inclusion and exclusion criteria and will receive a card of placebo.
Study: NCT03613987

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NAVA technology to synchronize NIPPV
Description: Neurally adjust ventilator assist is used to synchronize the NIPPV
Study: NCT02259907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KUC 7483 CL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KUC 7483 CL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat meal
Study: NCT04579601

Intervention type: PROCEDURE
Intervention: ERAS program
Description: We designed our centre's ERAS program through different measures during the preoperative, intraoperative and postoperative period. This program incluided received comprehensive multidisciplinary information, daily goals and expected discharge date, explained the expansión exercises, the video-assisted thoracoscopic surgery (VATS) under general anaesthesia combined with regional techniques, leaving only one chest tube at the end of the surgery, maintain normothermia, extubation after the end of the surgery, and early removal of the urinary catheter. From the time of extubation, the patients began oral tolerance and respiratory physiotherapy exercises. Also, the patients were allowed to walk around early.
Study: NCT02240693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03482583

Intervention type: DRUG
Group type: OTHER
Intervention: Nicotine Replacement Therapy
Description: Participants in CBT group will also be offered Nicotine Replacement Therapy if they are interested. NRT is the same regimen followed in AHEC and Quitline. In addition, weekly counseling will be provided to the participants remotely via vidyo, a video based platform.
Study: NCT02220543

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Back on Track intervention
Description: Biopsychosocial primary care intervention based on multidisciplinary pain rehabiliation programs. The Back on Track intervention comprises 4 individual sessions and 8 group sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Back on Track intervention
Description: Biopsychosocial primary care intervention based on multidisciplinary pain rehabiliation programs. The Back on Track intervention comprises 4 individual sessions and 8 group sessions.
Study: NCT03482583

Intervention type: OTHER
Group type: OTHER
Intervention: Referral to AHEC/Quitline
Description: Participants will be referred to local AHEC/Quitline for treatment

Intervention type: OTHER
Group type: OTHER
Intervention: Referral to AHEC/Quitline
Description: Participants will be referred to local AHEC/Quitline for treatment
Study: NCT02070796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine PR2.2.1
Description: Treatment A:~Rotigotine Transdermal patch 2 mg/24 hr (10 cm\^2) Test drug product PR2.2.1. Single application of 1 patch for 24 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rotigotine PR2.2.1
Description: Treatment A:~Rotigotine Transdermal patch 2 mg/24 hr (10 cm\^2) Test drug product PR2.2.1. Single application of 1 patch for 24 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine PR2.1.1
Description: Treatment B:~Rotigotine Transdermal patch 2 mg/24 hr (10 cm\^2) Reference drug product PR2.1.1. Single application of 1 patch for 24 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rotigotine PR2.1.1
Description: Treatment B:~Rotigotine Transdermal patch 2 mg/24 hr (10 cm\^2) Reference drug product PR2.1.1. Single application of 1 patch for 24 hours.
Study: NCT04206579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10% Dextrose
Description: A mixture of 150 cc dextrose 10% in oral formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10% Dextrose
Description: A mixture of 150 cc dextrose 10% in oral formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natrium Dextrose
Description: A mixture of 150 cc dextrose 10% + 20 cc sodium in oral formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natrium Dextrose
Description: A mixture of 150 cc dextrose 10% + 20 cc sodium in oral formulation
Study: NCT00372385

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pegylated Interferon Alfa 2a
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alfa 2a
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alfa 2a
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alfa 2a
Description: Solution for injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: tablet
Study: NCT03032471

Intervention type: OTHER
Intervention: There is no intervention for this study. Patients are allocated to the study groups based on whether or not DCI occurs.
Description: There is no intervention for this study. Patients are allocated to the study groups based on whether or not DCI occurs.

Intervention type: OTHER
Intervention: There is no intervention for this study. Patients are allocated to the study groups based on whether or not DCI occurs.
Description: There is no intervention for this study. Patients are allocated to the study groups based on whether or not DCI occurs.
Study: NCT00302627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamidronate
Description: 60mg or 90mg given at baseline, 6,12,18, and 24 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: baseline, 6,12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate
Description: baseline, 6,12 months
Study: NCT05691556

Intervention type: PROCEDURE
Intervention: HABIT ILE rehabilitation course
Description: The HABIT-ILE course, created by the Belgian team of Prof. Yannick Bleyenheuft, is a rehabilitation of the upper and lower limbs, following the concepts of structured motor learning and intensive therapy. The internships last 2 weeks and are performed on a multi-year basis since 2018 at the SSR pediatric, Fondation Ildys, Site de Ty Yann in Brest.~In this group, upper limb assessments are performed the week before and the week after the HABIT ILE training course

Intervention type: PROCEDURE
Intervention: botulinum toxin injections
Description: Toxin injections are used for their effect on the local reduction of spasticity after intramuscular injection. This treatment is usually offered to these children every 6 months or so for functional improvement.~These botulinum toxin injections are organized on a weekly basis in a pediatric day hospital (CHU Morvan in Brest).~In this group, upper limb assessments were performed 0-2 weeks before and then 4 to 6 weeks after the botulinum toxin injections (see table below), at the peak of the toxin's efficacy.
Study: NCT03559478

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sharp dissection with scalpel plus electrocautery to vessels
Description: A scalpel will be used for dissection for TKA implantation. Bleeding vessels will be managed as encountered with electrocautery. Electrocautery will not be used for dissection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrocautery for all dissection
Description: Skin incision will be made with a scalpel, but all other dissection will be performed with electrocautery.
Study: NCT02032303

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of coronary flow reserve

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of coronary flow reserve

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor loading

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel loading
Study: NCT01405937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vaniprevir
Description: vaniprevir capsules containing 150 mg vaniprevir, orally, two in the morning and two in the evening for 12 or 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vaniprevir
Description: vaniprevir capsules containing 150 mg vaniprevir, orally, two in the morning and two in the evening for 12 or 24 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peg-IFN
Description: peg-IFN 1.5 µg/kg once per week, subcutaneously (SC) for 24 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peg-IFN
Description: peg-IFN 1.5 µg/kg once per week, subcutaneously (SC) for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: Capsules containing 200 mg ribavirin, orally, 3 to 5 capsules, dosage based on participant weight (600 mg/day to 1000 mg/day), for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: Capsules containing 200 mg ribavirin, orally, 3 to 5 capsules, dosage based on participant weight (600 mg/day to 1000 mg/day), for 24 weeks
Study: NCT02949089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACH04
Description: The subjects will receive the study medication in each group
Study: NCT03067012

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oncometabolic reconstruction
Description: The length of biliopancreatic limb is 50cm and the length of Roux limb is 100cm. (long limb uncut Roux-en-Y gastrojejunostomy) These limbs are longer than the conventional uncut Roux-en-Y reconstruction for gastric cancer patients.
Study: NCT01541553

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Description: Cryotherapy of all visible AKs (4-8 lesions, baseline lesions) in the selected treatment area

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cryotherapy
Description: Cryotherapy of all visible AKs (4-8 lesions, baseline lesions) in the selected treatment area

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Field treatment with vehicle gel once daily for 3 consecutive days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ingenol metabute
Description: Field treatment with vehicle gel once daily for 3 consecutive days.
Study: NCT02939248

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crushed ticagrelor followed by morphine
Description: Crushed ticagrelor (180 mg) followed by morphine 5 mg intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crushed ticagrelor, morphine,naloxone
Description: Crushed ticagrelor (180 mg) orally followed by morphine 5 mg intravenously and naloxone 1 mg orally
Study: NCT02105350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK 162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study: NCT03652025

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: embolotherapy of incompetent gonadal and iliac veins
Description: minimally invasive
Study: NCT04293315

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improvement Cycles
Description: This is a multi-component intervention following the Institute for Healthcare Improvement (IHI)'s Collaborative Model for Achieving Breakthrough Improvement by implementing plan-do-study-act (PDSA) improvement cycles. The investigators will conduct 8 participative learning sessions for the primary care team. These sessions will be aimed at identifying opportunities for improvement oriented to the design and application of innovative approaches based on best practices.
Study: NCT02628756

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial injury
Description: Office hysteroscopy (Karl Storz, Tuttlingen, Germany)
Study: NCT00172107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALX1-11 50 mcg
Description: PTH(1-84) 50 mcg for subcutaneous injection into thigh or abdomen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo powder for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALX1-11 75mcg
Description: PTH(1-84)75 mcg for subcutaneous injection
Study: NCT02220543

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primary care as usual
Description: Regular physical therapy in primary care. Physical therapists are recommended by their profession (the Royal Dutch Society for Physical Therapy) to work according to a profession-specific guideline for the treatment of patients with low back pain in primary care settings. Maximally 12 individual sessions (30 minutes each) for a maximum of 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Primary care as usual
Description: Regular physical therapy in primary care. Physical therapists are recommended by their profession (the Royal Dutch Society for Physical Therapy) to work according to a profession-specific guideline for the treatment of patients with low back pain in primary care settings. Maximally 12 individual sessions (30 minutes each) for a maximum of 8 weeks.
Study: NCT00172107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALX1-11
Description: PTH (1-84) 100mcg for subcutaneous injection into thigh or abdomen
Study: NCT02902627

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non Invasive Monitoring Device (ANI)
Description: Pain measure by ANI monitor and with visual analogical scale
Study: NCT01906346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine
Description: Three active doses of cocaine will be made available for self-administration during experimental sessions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine
Description: Three active doses of cocaine will be made available for self-administration during experimental sessions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine
Description: Three active doses of cocaine will be made available for self-administration during experimental sessions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo cocaine will be made available for self-administration during experimental sessions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo cocaine will be made available for self-administration during experimental sessions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo cocaine will be made available for self-administration during experimental sessions.
Study: NCT00334555

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: different methods of partner notification
Description: comparing patient referral, partner delivered medications and field intervention to treat sex partners

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: partner delivered meds
Description: patient given meds to give to her partner

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: partner delivered meds
Description: patient given meds to give to her partner

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: field intervention
Description: health worker finds partners

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: field intervention
Description: health worker finds partners

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: field intervention
Description: health worker finds partners
Study: NCT01444209

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Iodine Implants
Description: Interstitial Radioactive Iodine Implants
Study: NCT02172339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium, solution ampoules
Study: NCT04021251

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: P0.2
Description: Investigational Medical Device collecting spectral raman data from tissue.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: P0.2
Description: Investigational Medical Device collecting spectral raman data from tissue.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: P0.2
Description: Investigational Medical Device collecting spectral raman data from tissue.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: P0.2
Description: Investigational Medical Device collecting spectral raman data from tissue.
Study: NCT02225353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone Cervical Pessary 6.3 g
Description: Progesterone Cervical Pessary low dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone 200 mg vaginal capsules
Description: Progesterone 200 mg vaginal capsules daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone Cervical Pessary 7.7 g
Description: Progesterone Cervical Pessary high dose
Study: NCT02463643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-215 10mg
Description: Z-215 10mg, capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-215 20mg
Description: Z-215 20mg, capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-215 20mg
Description: Z-215 20mg, capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Z-215 Placebo
Description: Z-215 placebo-matching capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-215 Placebo
Description: Z-215 placebo-matching capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-215 Placebo
Description: Z-215 placebo-matching capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole Sodium
Description: Rabeprazole Sodium 10mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole Sodium Placebo
Description: Rabeprazole Sodium Placebo placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole Sodium Placebo
Description: Rabeprazole Sodium Placebo placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole Sodium Placebo
Description: Rabeprazole Sodium Placebo placebo-matching tablets